Limits...
Immunotherapy of rat glioma without accumulation of CD4(+)CD25(+)FOXP3(+) regulatory T cells.

Feng E, Gao H, Su W, Yu C - Neural Regen Res (2012)

Bottom Line: Immunotherapy may be used for the treatment of glioblastoma multiforme; however, the induced immune response is inadequate when either T cells or dendritic cells are used alone.The frequency of peripheral blood CD4(+)CD25(+)FOXP3(+) regulatory T lymphocytes was significantly decreased following the combination therapy, and the rats survived for a longer period.Experimental findings indicate that the combined immunotherapy of glioma cell lysate-pulsed dendritic cell vaccination following adoptive transfer of T cells can effectively inhibit the growth of gliomas in rats, boost anti-tumor immunity and produce a sustained immune response while avoiding the accumulation of CD4(+)CD25(+)FOXP3(+) regulatory T lymphocytes.

View Article: PubMed Central - PubMed

Affiliation: Fuxing Hospital, Capital Medical University, Beijing 100038, China.

ABSTRACT
Immunotherapy may be used for the treatment of glioblastoma multiforme; however, the induced immune response is inadequate when either T cells or dendritic cells are used alone. In this study, we established a novel vaccine procedure in rats, using dendritic cells pulsed with C6 tumor cell lysates in combination with adoptive transfer of T lymphocytes from syngenic donors. On day 21 after tumor inoculation, all the rats were sacrificed, the brains were harvested for calculation of glioma volume, cytolytic T lymphocyte responses were measured by cytotoxic assay, and the frequency of regulatory T lymphocytes (CD4(+)CD25(+)FOXP3(+)) in the peripheral blood was investigated by flow cytometric analysis. The survival rate of rats bearing C6 glioma was observed. Results showed that the co-immunization strategy had significant anti-tumor potential against the pre-established C6 glioma, and induced a strong cytolytic T lymphocyte response in rats. The frequency of peripheral blood CD4(+)CD25(+)FOXP3(+) regulatory T lymphocytes was significantly decreased following the combination therapy, and the rats survived for a longer period. Experimental findings indicate that the combined immunotherapy of glioma cell lysate-pulsed dendritic cell vaccination following adoptive transfer of T cells can effectively inhibit the growth of gliomas in rats, boost anti-tumor immunity and produce a sustained immune response while avoiding the accumulation of CD4(+)CD25(+)FOXP3(+) regulatory T lymphocytes.

No MeSH data available.


Related in: MedlinePlus

Vaccination with dendritic cells (DCs) and T cells significantly suppressed glioma growth.(A–D) Representative photographs of coronal sections of the tumor's largest diameter from animals treated with (A) PBS, (B) T cells alone, (C) DCs alone, or (D) DCs +T cells (n = 6) were shown on day 21 after tumor inoculation.(E) The volume of C6 gliomas was calculated. Immunization of rats with C6 lysate-pulsed DCs followed by adoptive transfer of T cells significantly suppressed the growth of the tumor compared with PBS group (P < 0.01, unpaired t-test). The horizontal lines represent the mean of each group.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4308782&req=5

Figure 3: Vaccination with dendritic cells (DCs) and T cells significantly suppressed glioma growth.(A–D) Representative photographs of coronal sections of the tumor's largest diameter from animals treated with (A) PBS, (B) T cells alone, (C) DCs alone, or (D) DCs +T cells (n = 6) were shown on day 21 after tumor inoculation.(E) The volume of C6 gliomas was calculated. Immunization of rats with C6 lysate-pulsed DCs followed by adoptive transfer of T cells significantly suppressed the growth of the tumor compared with PBS group (P < 0.01, unpaired t-test). The horizontal lines represent the mean of each group.

Mentions: As shown in Figure 3, immunization of rats with C6 lysate-pulsed DCs followed by adoptive transfer of T cells significantly suppressed the growth of the tumor compared with the PBS group (P < 0.01).


Immunotherapy of rat glioma without accumulation of CD4(+)CD25(+)FOXP3(+) regulatory T cells.

Feng E, Gao H, Su W, Yu C - Neural Regen Res (2012)

Vaccination with dendritic cells (DCs) and T cells significantly suppressed glioma growth.(A–D) Representative photographs of coronal sections of the tumor's largest diameter from animals treated with (A) PBS, (B) T cells alone, (C) DCs alone, or (D) DCs +T cells (n = 6) were shown on day 21 after tumor inoculation.(E) The volume of C6 gliomas was calculated. Immunization of rats with C6 lysate-pulsed DCs followed by adoptive transfer of T cells significantly suppressed the growth of the tumor compared with PBS group (P < 0.01, unpaired t-test). The horizontal lines represent the mean of each group.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4308782&req=5

Figure 3: Vaccination with dendritic cells (DCs) and T cells significantly suppressed glioma growth.(A–D) Representative photographs of coronal sections of the tumor's largest diameter from animals treated with (A) PBS, (B) T cells alone, (C) DCs alone, or (D) DCs +T cells (n = 6) were shown on day 21 after tumor inoculation.(E) The volume of C6 gliomas was calculated. Immunization of rats with C6 lysate-pulsed DCs followed by adoptive transfer of T cells significantly suppressed the growth of the tumor compared with PBS group (P < 0.01, unpaired t-test). The horizontal lines represent the mean of each group.
Mentions: As shown in Figure 3, immunization of rats with C6 lysate-pulsed DCs followed by adoptive transfer of T cells significantly suppressed the growth of the tumor compared with the PBS group (P < 0.01).

Bottom Line: Immunotherapy may be used for the treatment of glioblastoma multiforme; however, the induced immune response is inadequate when either T cells or dendritic cells are used alone.The frequency of peripheral blood CD4(+)CD25(+)FOXP3(+) regulatory T lymphocytes was significantly decreased following the combination therapy, and the rats survived for a longer period.Experimental findings indicate that the combined immunotherapy of glioma cell lysate-pulsed dendritic cell vaccination following adoptive transfer of T cells can effectively inhibit the growth of gliomas in rats, boost anti-tumor immunity and produce a sustained immune response while avoiding the accumulation of CD4(+)CD25(+)FOXP3(+) regulatory T lymphocytes.

View Article: PubMed Central - PubMed

Affiliation: Fuxing Hospital, Capital Medical University, Beijing 100038, China.

ABSTRACT
Immunotherapy may be used for the treatment of glioblastoma multiforme; however, the induced immune response is inadequate when either T cells or dendritic cells are used alone. In this study, we established a novel vaccine procedure in rats, using dendritic cells pulsed with C6 tumor cell lysates in combination with adoptive transfer of T lymphocytes from syngenic donors. On day 21 after tumor inoculation, all the rats were sacrificed, the brains were harvested for calculation of glioma volume, cytolytic T lymphocyte responses were measured by cytotoxic assay, and the frequency of regulatory T lymphocytes (CD4(+)CD25(+)FOXP3(+)) in the peripheral blood was investigated by flow cytometric analysis. The survival rate of rats bearing C6 glioma was observed. Results showed that the co-immunization strategy had significant anti-tumor potential against the pre-established C6 glioma, and induced a strong cytolytic T lymphocyte response in rats. The frequency of peripheral blood CD4(+)CD25(+)FOXP3(+) regulatory T lymphocytes was significantly decreased following the combination therapy, and the rats survived for a longer period. Experimental findings indicate that the combined immunotherapy of glioma cell lysate-pulsed dendritic cell vaccination following adoptive transfer of T cells can effectively inhibit the growth of gliomas in rats, boost anti-tumor immunity and produce a sustained immune response while avoiding the accumulation of CD4(+)CD25(+)FOXP3(+) regulatory T lymphocytes.

No MeSH data available.


Related in: MedlinePlus